A Study of Mirikizumab (LY3074828) in Participants With Active Crohn's Disease

NCT02891226 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

191

Enrollment

INDUSTRY

Sponsor class

Conditions

Crohn's Disease

Interventions

DRUG: Mirikizumab
DRUG: Placebo

Sponsor

Eli Lilly and Company